Navigation Links
Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity
Date:12/1/2008

St. Jude study shows the Prox1 gene is a two-way switch that, if turned off, causes lymphatic endothelial cells to be reprogrammed so that they lose their identity and become more like blood endothelial cells

MEMPHIS, Tenn., Dec. 1 /PRNewswire-USNewswire/ --Scientists at St. Jude Children's Research Hospital have discovered that a certain differentiated cell type is so ready to change its identity that it requires the constant expression of a gene called Prox1 to dissuade it.

The researchers showed that Prox1 acts as a two-way switch whose inactivity is sufficient to reprogram a specialized type of cell, called a lymphatic endothelial cell (LEC). In the absence of active Prox1, the LEC actually loses its identity and assumes characteristics of a blood endothelial cell (BEC), which plays a different role in the body. Endothelial cells line the inside of blood and lymphatic vessels. The results of the study appear in the Dec. 1, 2008, issue of the journal Genes & Development.

The new finding is important because it helps to explain how during embryogenesis a critical set of vessels called the lymphatic vasculature arises from veins; and how lymphatic vessels can eventually lose their characteristics and acquire features typical of blood vessels and transport blood -- a trick that might, for example, let the body quickly build up a supply of additional blood vessels when there is an emergency need for more nourishment in a certain area. A switch from lymphatic to blood vessels might also be triggered by certain tumors trying to nourish their own growth.

The lymphatic vasculature is a vital network of vessels that performs important housekeeping functions in the body. Specifically, it drains fluids that normally escape from capillaries, which provide nutrients to the body's cells. The lymphatic vasculature is also part of the immune system that
'/>"/>

SOURCE St. Jude Children's Research Hospital
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
3. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
4. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
5. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
6. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
9. RICE MEMORIAL HOSPITAL PHARMACY STAFF EXPERIENCES A 55% REDUCTION IN TIME SPENT MANAGING PATIENT-SPECIFIC MEDICATIONS USING OMNICELL SINGLEPOINTE SOLUTION
10. Novare Announces Completion of First Pediatric Single Port Spleen Removal Using RealHand(R) HD Instruments
11. Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... DIEGO , May 23, 2013 Neurocrine Biosciences, ... Kevin Gorman , President and Chief Executive Officer ... 38 th Annual dbAccess Health Care Conference in Boston.   ... May 30 at 11:20 a.m. Eastern Time / 8:20 a.m. ... accessed on the Company,s website at http://www.neurocrine.com . ...
(Date:5/23/2013)... 2013  Haemonetics Corporation (NYSE: HAE ) announced ... EVP-Business Development, will present at The Deutsche Bank 38 th ... MA on May 29, 2013 at 1:30pm Eastern ... The public may access Mr. Lindop,s presentation live via ... Haemonetics (NYSE: HAE ) is a ...
(Date:5/23/2013)... Hearing health affects a man,s lifestyle, and if ... and professionally engaged, he should address any hearing loss he ... Better Hearing Institute (BHI) is delivering to men ... Week , which leads up to and includes Father,s Day. ... through June 16. To help men address ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4
... Patients with active moderate to severe rheumatoid arthritis ... or adalimumab (Humira ® ) and who were actively ... from baseline at week 10, and sustained response through ... 26 results from the RESTART study were presented for ...
... LLC, the image analysis and pattern recognition technology provider, ... of $244,479.25 under the U.S. Government,s Affordable Care Act. ... projects that show significant potential to produce new therapies, ... health care costs or advance the goal of curing ...
Cached Medicine Technology:New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 2New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 3New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 4New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 5New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 6New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 7Parascript Awarded $244,479.25 Affordable Care Act Grant From the U.S. Government 2
(Date:5/25/2013)... On May 20, 2013 the Sydney ... to discuss or plan for their eventual demise, but it ... released a Must-Do List to help people properly arrange for ... a personal fact sheet.” , While not a formal document, ... personal data. It may include a summary of assets, ...
(Date:5/25/2013)... 25, 2013 According to a ... Market, 2013–2018", published by MarketsandMarkets is expected to ... of 5.54% which analyzes and studies the major ... Europe, Asia, and Rest of the World. , ... Tables , 87 Figures , ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 The Slim Weight ... effectiveness and results. This is due to the highly sought ... patches. Slim weight patch offers an extra 2 months supply ... fitness goals and get the body you desire faster than ... Official Website , With Slim weight patch consumers can ...
(Date:5/25/2013)... May 25, 2013 Ayurveda is ... means "knowledge or wisdom of life". While a medical science, ... the transformation of consciousness. Its fundamental philosophy is that disease ... our environment. It believes that in order to re-establish optimal ... harmony and then adopt a life style which brings us ...
(Date:5/25/2013)... OH (PRWEB) May 25, 2013 The ... filed an Imprelis lawsuit on behalf of 23 ... no. N13C-04-280 EMD) was filed on April 25, 2013 and ... As with previously filed Wright & Schulte Imprelis lawsuits, this ... New Castle County. , This Imprelis lawsuit ...
Breaking Medicine News(10 mins):Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4Health News:Slim Weight Patch Advanced Weight Loss System Offers Extra Two Month Supply and Membership for Maximum Weight Loss 2Health News:Ayurveda Education Programs Offered by the California College of Ayurveda Include Panchakarma Certification, Practitioner Courses, and Body Therapy Classes 2Health News:Imprelis Lawsuit Filed on Behalf of Multiple Property Owners Nationwide Who Allege Imprelis Use Resulted In Extensive Tree Damage and Death, Reports Wright & Schulte 2Health News:Imprelis Lawsuit Filed on Behalf of Multiple Property Owners Nationwide Who Allege Imprelis Use Resulted In Extensive Tree Damage and Death, Reports Wright & Schulte 3Health News:Imprelis Lawsuit Filed on Behalf of Multiple Property Owners Nationwide Who Allege Imprelis Use Resulted In Extensive Tree Damage and Death, Reports Wright & Schulte 4
... & Lomb, the global eye health company, has entered ... for the development of certain intraocular lens (IOL) materials. ... has obtained the rights to Santen,s hydrophobic acrylic polymers, ... worldwide. Santen reserves the right for the use of ...
... March 3 Marinus Pharmaceuticals, Inc. today announced that ... clinical trial investigating the safety and efficacy of ganaxolone ... a type of epilepsy. In this trial, ganaxolone ... Efficacy was seen in the first week of ...
... supplies has unveiled their annual 2009 list of what to do if ... ... Nationwide Medical/Surgical , a distributor of the flu vaccine and flu ... if exposed to the flu virus., , ,The flu is a highly ...
... Study finds it alters levels of hormones, could raise risk ... 2 -- Working the night shift might lead to hormonal ... heart disease, researchers say. , "In the long run, the ... the regulation of body weight -- leptin, insulin, cortisol -- ...
... KIRKLAND, Wash., Feb 26 ProteoTech Inc. announced ... from The Michael J. Fox Foundation for Parkinson,s ... (Philadelphia, PA), ProteoTech scientists will utilize ProteoTech,s small ... agents that will allow doctors to use PET ...
... 2 Speaker Nancy Pelosi released the following ... Sebelius as Secretary of the Department of Health and ... leader who has worked to expand health care access ... drugs. "Governor Sebelius, deep understanding of health care issues ...
Cached Medicine News:Health News:Bausch & Lomb, Santen Strike Licensing Agreement for IOL Development 2Health News:Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures 2Health News:Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures 3Health News:Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults With Partial Onset Seizures 4Health News:Nationwide Medical/Surgical Reveals Their Help Sheet For Those Infected with Influenza Virus 2Health News:Night Shift Work Hard on the Heart 2Health News:Night Shift Work Hard on the Heart 3Health News:ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinson's Disease Research to Develop Tools for Imaging Alpha-Synuclein Aggregation in Living Parkinson's Brain 2
This is long known for its purity and mildness, Castile Soap is also an effective cleaning agent that is used in a variety of applications. It rinses clean while leaving the skin soft and healthy....
Upon application to intact skin, Skin-Prep* protective wipes forms a protective film that prepares the skin for the attachment of drainage tubes, external catheters, adhesive dressings and can be...
Triad Plus Sterile Isopropyl Alcohol 70% USP Prep Pads are medium size. Each package is terminally sterilized, ensuring the safest possible product....
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
Medicine Products: